- IntroductionRabies is a preventable yet fatal disease that is responsible forapproximately 59000 deaths each year.However, widespread underreporting of rabies cases means that the actual numberof deaths is likely to be higher. Poor and rural populationsare disproportionately affected, with the majority of deathsoccurring in children younger than 15years in Asia and Af-rica.2Ninety-nine per cent of human rabies cases result from dog bites and, once symptoms begin, the disease is almostinvariably fatal.3Human rabies is preventable through canine vaccination to eliminate rabies at its source or by administering rabies vaccines and immunoglobulin following bites,scratches or saliva exposure from suspected rabid mammals (i.e. postexposure prophylaxis).4Another preventive strategy is pre-exposure prophylaxis, which involves giving a series of intramuscular or intradermal injections of rabies vaccine to prime the immune system. This enables fast recall of memory immune responses once a person is re-exposed to the virus.4Moreover, people who have received pre-exposure prophylaxis require fewer doses of postexposure rabies vaccine and can be treated without rabies immunoglobulin, which is costly and difficult to procure.4Although preventing rabies in dogs is the most cost-effective way of preventing human rabies deaths, pre-exposure prophylaxisis valuable for people at a high disease risk,
- 5particularly inareas where controlling disease in the animal reservoir is difficult or hasnot been implemented and in areas where access to postexposure prophylaxis and rabies immunoglobulin is unreliable or nonexistent. National pre-exposure prophylaxisprogrammes for high-risk populations have been implemented in Peru and the Philippines.6,7In 2010, a World Health Organization (WHO) position paper on rabies vaccines calledfor studies on the feasibility, cost–effectiveness and long-term impact of incorporatingvaccines derived from cell culture or embryonated eggs into immunization programmesfor children where canine rabies is a public health problem.5The paper also made recommendations on pre-exposure prophylaxis regimens and on thefrequency of booster vaccinations and serological surveillance for at-risk individuals,such as veterinarians. The aim of this study was to review the scientific literature published between 2007 and 2016, as well as field data, to assess the current use and cost–effectiveness of pre-exposure rabies prophylaxis(excluding travel vaccines), particularly in children and in high-risk settings, in the context of recommendations made inthe 2010 WHO rabies vaccine position paper on pre-exposure prophylaxis and booster vaccine administration
Leta i den här bloggen
onsdag 1 mars 2017
Lancetissa rabieksesta uutta
http://www.who.int/bulletin/volumes/95/3/16-173039.pdf
Prenumerera på:
Kommentarer till inlägget (Atom)
Inga kommentarer:
Skicka en kommentar